Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Biodexa Pharmaceticals

Healthcare US BDRX

3.01USD
-0.05(1.63%)

Last update at 2026-06-22T20:00:00Z

Day Range

3.003.12
LowHigh

52 Week Range

2.8696.50
LowHigh

Fundamentals

  • Previous Close 3.06
  • Market Cap2.59M
  • Volume12011
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-8.59300M
  • Revenue TTM0.08M
  • Revenue Per Share TTM0.43
  • Gross Profit TTM -3.96100M
  • Diluted EPS TTM-3.37

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -6.34680M -5.97900M -7.48500M -8.48800M -6.10600M
Minority interest - - - - -
Net income -6.24410M -5.72900M -7.07900M -7.65600M -5.46000M
Selling general administrative 4.84M 3.79M 4.34M 4.54M 2.95M
Selling and marketing expenses - - - - -
Gross profit -0.18486M -5.43700M -3.68600M -4.41200M -4.07600M
Reconciled depreciation 0.19M 0.25M 0.28M 0.34M 0.40M
Ebit -8.26873M -9.19900M -7.44400M -8.93200M -6.99800M
Ebitda -8.08388M -9.08200M -7.16100M -8.75500M -6.78500M
Depreciation and amortization 0.18M 0.12M 0.28M 0.18M 0.21M
Non operating income net other - - - - -
Operating income -8.26873M -9.19900M -8.01400M -8.93200M -6.99800M
Other operating expenses 8.27M 9.20M 8.39M 9.16M 6.64M
Interest expense 0.07M 0.17M 0.04M 0.05M 0.04M
Tax provision -0.10500M -0.25000M -0.40600M -0.83200M -0.64600M
Interest income 0.09M 0.17M 0.08M 0.03M 0.00000M
Net interest income -0.14000M 0.00200M 0.04M -0.02400M -0.04400M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.10270M -0.25000M -0.40600M 0.83M 0.65M
Total revenue 0.00000M 0.00000M 0.38M 0.70M 0.58M
Total operating expenses 8.08M 3.76M 4.33M 4.05M 1.99M
Cost of revenue 0.18M 5.44M 4.07M 5.11M 4.65M
Total other income expense net 1.92M 3.22M 0.53M 0.44M 0.89M
Discontinued operations - - - - -
Net income from continuing ops -6.38400M -5.72900M -7.07900M -7.65600M -5.46000M
Net income applicable to common shares - - - - -5.46000M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 18.15M 14.78M 10.54M 5.53M 12.91M
Intangible assets 5.64M 5.65M 2.94M 0.00600M -
Earning assets - - - - -
Other current assets 3.68M 6.43M 1.06M - -
Total liab 6.76M 6.46M 5.86M 2.36M 2.46M
Total stockholder equity 11.38M 8.32M 4.68M 3.16M 10.45M
Deferred long term liab - - - - -
Other current liab 5.49M 2.20M 4.16M 0.10M 0.60M
Common stock 14.07M 6.69M 1.19M 1.11M 0.10M
Capital stock 14.10M 6.69M 1.19M 1.11M 0.10M
Retained earnings -102.62430M -150.42400M -144.76700M -135.33600M -127.80300M
Other liab - - - - -
Good will 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Other assets - - - - -
Cash 8.52M 1.67M 5.97M 2.84M 10.06M
Cash and equivalents - - - - -
Total current liabilities 6.12M 5.03M 5.57M 1.90M 1.84M
Current deferred revenue 0.57M 1.47M 0.93M 0.20M -
Net debt -8.45811M -0.94200M -5.50700M -2.21200M -9.29100M
Short term debt 0.06M 0.61M 0.17M 0.16M 0.15M
Short long term debt - - - 0.00000M 0.00000M
Short long term debt total 0.06M 0.73M 0.46M 0.62M 0.77M
Other stockholder equity 98.75M 99.06M 95.25M 84.39M 138.16M
Property plant equipment - - - - 1.15M
Total current assets 12.42M 8.81M 7.03M 4.69M 11.76M
Long term investments - - - - -
Net tangible assets - - - - 10.45M
Short term investments - - - - -
Net receivables 0.22M 0.71M 0.70M 1.48M 1.70M
Long term debt - - - - 0.00000M
Inventory - - -0.70400M - -
Accounts payable 0.10M 0.71M 0.31M 1.45M 1.09M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.19M 53.00M 53.00M 53.00M -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 5.73M 5.97M 3.51M 0.84M 1.15M
Capital lease obligations 0.06M 0.73M 0.46M 0.62M 0.77M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.59800M -0.26500M -0.22000M -0.27800M
Change to liabilities - - - - -0.13000M
Total cashflows from investing activities -0.65825M -0.59800M -0.26500M - -0.27800M
Net borrowings -0.69600M 0.24M -0.18800M - -0.21500M
Total cash from financing activities 12.77M 8.56M 10.23M 0.05M 8.80M
Change to operating activities - - - - -
Net income -6.24410M -5.72900M -7.07900M -7.65600M -5.46000M
Change in cash 6.97M -4.30200M 3.13M -7.22100M 2.51M
Begin period cash flow 1.55M 5.97M 2.84M 10.06M 7.55M
End period cash flow 8.52M 1.67M 5.97M 2.84M 10.06M
Total cash from operating activities -5.39414M -12.26100M -6.82600M -7.04800M -6.00800M
Issuance of capital stock 13.75M 8.31M 10.43M 0.24M 9.04M
Depreciation 0.18M 0.25M 0.28M 0.34M 0.40M
Other cashflows from investing activities - -0.58900M -0.23900M - -
Dividends paid 0.00000M 0.00000M 0.00000M 0.00000M -
Change to inventory - - - - -
Change to account receivables 2.57M -5.97500M 0.36M - -0.48700M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.24061M - -0.01300M -0.01800M -0.12700M
Change to netincome - - - - -0.33400M
Capital expenditures 0.00196M 0.77M 0.26M 0.06M 0.32M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.68M -3.73600M -0.04900M 0.52M -0.61700M
Stock based compensation 0.17M 0.28M 0.03M 0.12M 0.09M
Other non cash items -1.01330M -3.08300M 0.40M 0.45M -0.42300M
Free cash flow -5.39610M -13.03500M -7.08900M -7.11000M -6.32800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BDRX
Biodexa Pharmaceticals		 -0.05 1.63% 3.01 - - 0.58 0.18 4.70 0.03
NVO
Novo Nordisk A/S		 2.69 6.23% 45.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 15.16 3.36% 466.79 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.56 0.42% 612.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Biodexa Pharmaceticals

1 Caspian Point, Cardiff, United Kingdom, CF10 4DQ

Key Executives

Name Title Year Born
Mr. Stephen A. Stamp CEO, CFO, Company Secretary & Director 1962
Dr. Dmitry Zamoryakhin M.D. Chief Scientific Officer & Chief Medical Officer 1980
Dr. Daniel Palmer MBA, Ph.D. Vice President of Technology NA
Ms. Nicola Tuckwell VP & Head of Clinical Operations NA
Ms. Fiona Sharp Group Financial Controller NA
Mr. Steve Ellul Chief Business Officer NA
Mr. Stephen Anthony Stamp CEO, CFO, Company Secretary & Director 1961
Dr. Gary A. Shangold CPI, FACOG, M.D. Chief Medical Officer 1954
Mr. Stephen Anthony Stamp CEO & Director 1961
Ms. Fiona Mary Powell Company Secretary, CFO & Director 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.